Compare Natera Inc. Common Stock (NTRA) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Rent the Runway Inc — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Rent the Runway Inc trades at $1.71 (market cap $57.68M). The key difference: Natera Inc. Common Stock is far larger — about 988.7× Rent the Runway Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Rent the Runway Inc for 56 Days on average.
| NTRA | RENT | |
|---|---|---|
Market Cap | $57.03B | $57.68M |
Volume | 1,131,157 | 79,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $9.39 |
52-Week Low | $179.42 | $1.55 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $56.18B | $224.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RENT trades at $1.78, down 2.73% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q2 2026 revenue of $97.7 million, up 20.8% year-over-year, and named Paige Thomas as CEO. Despite negative shareholder equity and a high debt load, profitability is improving, with net income margin turning positive in 2026. Analyst sentiment is cautiously optimistic with a 42% buy rating.
The outlook is cautiously optimistic as revenue growth accelerates and cost controls improve margins, but significant risks remain from negative equity, high debt, and ongoing legal investigations. The stock presents a high-risk, high-reward opportunity contingent on successful execution of the turnaround plan under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
